Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 310

1.

The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.

Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR.

J Pediatr Hematol Oncol. 2005 Jun;27(6):326-9.

PMID:
15956887
2.

Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.

Iyer P, Molitch ME.

Endocr Pract. 2011 May-Jun;17(3):e55-8. doi: 10.4158/EP10369.CR.

PMID:
21324816
3.

Diagnosis and drug therapy of prolactinoma.

Ciccarelli E, Camanni F.

Drugs. 1996 Jun;51(6):954-65. Review.

PMID:
8736617
4.
5.

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.

Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60.

PMID:
10931080
6.

Dopamine receptor agonists for treating prolactinomas.

Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G.

Expert Opin Investig Drugs. 2002 Jun;11(6):787-800. Review.

PMID:
12036422
7.

Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.

Kawabata Y, Ueno Y, Horikawa F, Miyake H, Miki N, Ono M.

Surg Neurol. 2008 Jan;69(1):85-8; discussion 88. Epub 2007 Oct 29.

PMID:
17967478
8.

Non-surgical management of cystic prolactinomas.

Bahuleyan B, Menon G, Nair S, Rao BR, Easwer HV, Krishna K.

J Clin Neurosci. 2009 Nov;16(11):1421-4. doi: 10.1016/j.jocn.2009.03.024. Epub 2009 Aug 20.

PMID:
19699096
9.

Late development of resistance to bromocriptine in a patient with macroprolactinoma.

Delgrange E, Crabbé J, Donckier J.

Horm Res. 1998;49(5):250-3.

PMID:
9568811
10.

Dopamine resistance of prolactinomas.

Molitch ME.

Pituitary. 2003;6(1):19-27. Review.

PMID:
14674720
11.

Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.

Cesario F, Borretta G, Meineri I, Muratori M, Pizzocaro A, Beck-Peccoz P.

J Pediatr Endocrinol Metab. 1997 Mar-Apr;10(2):231-6.

PMID:
9364359
12.
13.

The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.

Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.

Pol Arch Med Wewn. 2003 May;109(5):489-95.

PMID:
14768178
14.

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.

Delgrange E, Maiter D, Donckier J.

Eur J Endocrinol. 1996 Apr;134(4):454-6.

PMID:
8640297
15.

Pharmacologic resistance in prolactinoma patients.

Molitch ME.

Pituitary. 2005;8(1):43-52. Review.

PMID:
16411068
16.

Cabergoline and quinagolide therapy for prolactinomas.

Webster J.

Clin Endocrinol (Oxf). 2000 Nov;53(5):549-50. No abstract available.

PMID:
11106914
17.

Treatment of macroprolactinoma with cabergoline: a study of 85 patients.

Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF.

Clin Endocrinol (Oxf). 1997 Apr;46(4):409-13.

PMID:
9196602
18.

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.

Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.

J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52.

PMID:
10852458
19.

Hyperprolactinemia: pathophysiology and management.

Verhelst J, Abs R.

Treat Endocrinol. 2003;2(1):23-32. Review.

PMID:
15871552
20.

Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.

Behan LA, Draman MS, Moran C, King T, Crowley RK, O'Sullivan EP, Smith D, Thompson CJ, Agha A.

Pituitary. 2011 Dec;14(4):362-6. doi: 10.1007/s11102-009-0168-0. Review.

PMID:
19191028

Supplemental Content

Support Center